Department of Medical Biology, University of Zagreb School of Medicine, Šalata 3, 10000 Zagreb, Croatia.
Scientific Group for Research on Epigenetic Biomarkers, University of Zagreb School of Medicine, Šalata 3, 10000 Zagreb, Croatia.
Dis Markers. 2020 Nov 6;2020:8841880. doi: 10.1155/2020/8841880. eCollection 2020.
Testicular germ cell tumors (TGCTs) are ever more affecting the young male population. Germ cell neoplasia (GCNIS) is the origin of TGCTs, namely, seminomas (SE) and a heterogeneous group of nonseminomas (NS) comprising embryonal carcinoma, teratoma, yolk sac tumor, and choriocarcinoma. Response to the treatment and prognosis, especially of NS, depend on precise diagnosis with a necessity for discovery of new biomarkers. We aimed to perform comprehensive analysis at the DNA, RNA, and protein levels of six prospective (, , , , , and ) and six known TGCT biomarkers (, , , , , and ) and assess its congruence with histopathological analysis in all forms of TGCTs. Cancer Hallmarks Analytics Tool, the Search Tool for the Retrieval of Interacting Genes/Proteins database, and UALCAN, an interactive web resource for analyzing cancer OMICS data, were used. In 108 TGCT and 48 tumor-free testicular samples, the immunoreactivity score (IRS) was calculated. SE showed higher frequency in DNA alteration, while DNA methylation was significantly higher for all prospective biomarkers in NS. In GCNIS, we assessed the clinical positivity of and in 52% and 62% of samples, respectively, in contrast to low or nil positivity in healthy seminiferous tubules, TGTCs as a group, SE, NS, or all NS components. Although present in approximately 80% of healthy seminiferous tubules (HT) and GCNIS, was diagnostically positive in 64% of TGCTs, while it was positive in 82% of NS versus 29% of SE. Results at the DNA, mRNA, and protein levels on putative and already known biomarkers were included in the suggested panels that may prove to be important for better diagnostics of various forms of TGCTs.
睾丸生殖细胞肿瘤 (TGCTs) 越来越多地影响年轻男性群体。生殖细胞肿瘤起源于 GCNIS,即精原细胞瘤 (SE) 和一组异质性的非精原细胞瘤 (NS),包括胚胎癌、畸胎瘤、卵黄囊肿瘤和绒毛膜癌。治疗反应和预后,特别是 NS,取决于精确的诊断,需要发现新的生物标志物。我们旨在对 6 种有前途的 (、、、、、和 ) 和 6 种已知的 TGCT 生物标志物 (、、、、、和 ) 进行综合分析,评估其与所有形式 TGCT 的组织病理学分析的一致性。癌症标志分析工具、搜索工具检索互作基因/蛋白数据库和 UALCAN,一个用于分析癌症 OMICS 数据的交互式网络资源,被用于分析。在 108 例 TGCT 和 48 例无肿瘤睾丸样本中,计算了免疫反应评分 (IRS)。SE 在 DNA 改变中表现出更高的频率,而在 NS 中所有前瞻性生物标志物的 DNA 甲基化水平显著更高。在 GCNIS 中,我们评估了在 52%的样本中 52%和 62%的样本中的临床阳性率,而在健康的生精小管中为低或阴性,TGTCs 作为一组、SE、NS 或所有 NS 成分。虽然大约存在于 80%的健康生精小管 (HT) 和 GCNIS 中,但在 64%的 TGCT 中,而在 82%的 NS 中,而在 29%的 SE 中。在 DNA、mRNA 和蛋白质水平上对潜在的和已知的生物标志物的结果包括在建议的面板中,这可能证明对各种形式的 TGCT 的更好诊断是重要的。